BR112017018944A2 - método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) - Google Patents
método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)Info
- Publication number
- BR112017018944A2 BR112017018944A2 BR112017018944A BR112017018944A BR112017018944A2 BR 112017018944 A2 BR112017018944 A2 BR 112017018944A2 BR 112017018944 A BR112017018944 A BR 112017018944A BR 112017018944 A BR112017018944 A BR 112017018944A BR 112017018944 A2 BR112017018944 A2 BR 112017018944A2
- Authority
- BR
- Brazil
- Prior art keywords
- carbinoid
- drug
- treating
- condition
- disease state
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562126757P | 2015-03-02 | 2015-03-02 | |
US201662299260P | 2016-02-24 | 2016-02-24 | |
PCT/US2016/020446 WO2016141056A1 (en) | 2015-03-02 | 2016-03-02 | Topical regional neuro-affective therapy with cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017018944A2 true BR112017018944A2 (pt) | 2018-05-15 |
Family
ID=56849015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017018944A BR112017018944A2 (pt) | 2015-03-02 | 2016-03-02 | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) |
Country Status (11)
Country | Link |
---|---|
US (4) | US20160256410A1 (pt) |
EP (1) | EP3265081A4 (pt) |
JP (1) | JP2018507262A (pt) |
CN (1) | CN107530318A (pt) |
AU (1) | AU2016226267A1 (pt) |
BR (1) | BR112017018944A2 (pt) |
CA (1) | CA2978605A1 (pt) |
HK (2) | HK1244715A1 (pt) |
IL (1) | IL254294A0 (pt) |
MX (1) | MX2017011280A (pt) |
WO (1) | WO2016141056A1 (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2549277B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
CN107952075A (zh) * | 2016-10-14 | 2018-04-24 | 汉义生物科技(北京)有限公司 | 一种含***二酚的组合物及其应用 |
CN107951869A (zh) * | 2016-10-14 | 2018-04-24 | 汉义生物科技(北京)有限公司 | 含有***二酚的药物制剂及其应用 |
CN108079305A (zh) * | 2016-11-23 | 2018-05-29 | 汉义生物科技(北京)有限公司 | ***二酚与三环类抗抑郁药的药物组合物及其用途 |
CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技(北京)有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与***二酚的组合物及其应用 |
EP3488220A4 (en) * | 2016-11-29 | 2020-03-04 | Axim Biotechnologies, Inc. | CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND NICOTINE |
CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技(北京)有限公司 | ***二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
GB2557921A (en) * | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
US20200215022A1 (en) * | 2016-12-20 | 2020-07-09 | Tilray, Inc. | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
CA3053500A1 (en) * | 2017-02-15 | 2018-08-23 | Botanix Pharmaceuticals Ltd | Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases |
JP2020508992A (ja) * | 2017-02-15 | 2020-03-26 | ボタニクス ファーマシューティカルズ リミテッド | ざ瘡の処置のためのカンナビノイドの製剤 |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
EP3600285A4 (en) * | 2017-03-27 | 2021-01-13 | Patagonia Pharmaceuticals, LLC | TOPICAL COMPOSITIONS AND METHODS OF TREATMENT |
CN109498606A (zh) | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有***二酚和/或次***二酚的组合物及其在治疗痛经中的应用 |
EP3687513B1 (en) | 2017-09-28 | 2021-12-15 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome and autism with cannabidiol |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US20200330378A1 (en) * | 2018-01-03 | 2020-10-22 | Icdpharma Ltd. | Taste-enhanced cannabinoid submicron emulsion syrup compositions |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
CN112020352A (zh) * | 2018-01-24 | 2020-12-01 | 博塔尼克斯制药有限公司 | 用于痤疮的***素给药方案 |
AU2019210704A1 (en) * | 2018-01-24 | 2020-08-06 | Botanix Pharmaceuticals Ltd | Cannabinoid dosing regime for psoriasis |
WO2019144190A1 (en) * | 2018-01-24 | 2019-08-01 | Botanix Pharmaceuticals Ltd | Cannabinoid dosing regime for dermatitis and inflammatory skin conditions |
BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
WO2019194871A1 (en) * | 2018-04-05 | 2019-10-10 | Erbst Steven Robert | Therapeutic elastic bandage for modulating the endocannabinoid system |
CA3096842A1 (en) * | 2018-04-09 | 2019-10-17 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US10668045B2 (en) * | 2018-07-12 | 2020-06-02 | Bright Green Corporation | Topical massage oil and cream containing CBD, CBN, curcumin and Boswellia resin |
US20210322312A1 (en) * | 2018-08-17 | 2021-10-21 | Kirsten K. Shepard | Cannabidiol composition and methods thereof |
US10588979B1 (en) * | 2018-09-17 | 2020-03-17 | Cody D. Freeze | Cannabinoid and terpene-infused topical cream |
US20210361612A1 (en) * | 2018-10-15 | 2021-11-25 | Amnon Vardi | Slow release cannabinoids and products thereof |
EP3643303A1 (en) * | 2018-10-22 | 2020-04-29 | InnovativeHealth Group SL | Compounds for use in the treatment or prevention of fibrotic diseases; pharmaceutical, cosmetic compositions and uses thereof |
WO2020117288A1 (en) * | 2018-12-07 | 2020-06-11 | Mckinney Jeffrey A | Deuterated agonists and methods of use |
WO2020121260A1 (en) | 2018-12-14 | 2020-06-18 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
JP7303969B2 (ja) * | 2019-01-08 | 2023-07-06 | 株式会社ワンインチ | 電子タバコ用液体組成物及びそれを有する電子タバコ |
US20200254271A1 (en) * | 2019-02-13 | 2020-08-13 | Chiscan Holdings, Llc | Devices and methods for application of non-thermal plasma |
CN109718229B (zh) * | 2019-02-15 | 2021-05-28 | 烟台汉麻生物技术有限公司 | 一种抗炎药物组合物及其应用 |
US11752127B2 (en) | 2019-04-01 | 2023-09-12 | Virbac Corporation | Methods and compositions for treatment of anxiety in animals |
US20200352826A1 (en) * | 2019-05-06 | 2020-11-12 | Atomic Health, Inc. | Systems And Methods For Manufacturing Cannabis Edibles, And Resulting Edible Products |
US20220378718A1 (en) * | 2019-05-28 | 2022-12-01 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
WO2020243352A1 (en) * | 2019-05-28 | 2020-12-03 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
JP2022540553A (ja) * | 2019-06-25 | 2022-09-16 | エービー7 イノベーション エスエーエスユー | カンナビノイド系ポリマーマトリックスの形態のデバイス |
BR112021026374A2 (pt) * | 2019-06-26 | 2022-06-07 | Cannpal Animal Therapeutics Ltd | Composição de cbd |
US10588871B1 (en) | 2019-06-28 | 2020-03-17 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
US20210022993A1 (en) * | 2019-07-22 | 2021-01-28 | Novilla Pharmaceuticals, Inc. | Method of remotely controlling pain |
CA3147357A1 (en) * | 2019-08-21 | 2021-02-25 | Stephen Goldner | Medical apparatus with cannabis sativa l. |
MX2022003193A (es) * | 2019-09-17 | 2022-04-11 | Zynerba Pharmaceuticals Inc | Tratamiento de encefalopatia asociada al gen syngap1. |
CN114727960A (zh) | 2019-10-03 | 2022-07-08 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 数个脂质体***素及其用途 |
CA3155176A1 (en) * | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
US20210251918A1 (en) * | 2019-10-11 | 2021-08-19 | Pike Therapeutics Inc., 1219014 B.C. Ltd | Pharmaceutical composition and method for treating seizure disorders |
CA3160634A1 (en) * | 2019-11-08 | 2021-05-14 | Vella Bioscience, Inc. | Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders |
CA3160595A1 (en) * | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product comprising a cannabinoid |
US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
US20230158091A1 (en) * | 2020-03-19 | 2023-05-25 | New York Medical College | Cannabinoid medical carrier |
US20210346310A1 (en) * | 2020-04-20 | 2021-11-11 | Pike Therapeutics, Inc. | Transdermal and/or topical, pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain |
JP2023537302A (ja) * | 2020-08-03 | 2023-08-31 | エスシーアイ スパーク リミティド | 微小血管の健常性を維持するための方法 |
CN115884761A (zh) * | 2020-08-17 | 2023-03-31 | 长矛治疗股份有限公司 | ***素的透皮药物制剂 |
US20220054446A1 (en) * | 2020-08-18 | 2022-02-24 | Yvette Rose Webb | Targeted treatment with a topical cream of cannabinoids, terpenes, and essential oils |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
WO2022159506A1 (en) * | 2021-01-19 | 2022-07-28 | Merit Therapeutics, Inc. | Deuterated cannabidiol compounds |
CN117479930A (zh) * | 2021-04-08 | 2024-01-30 | 长矛治疗股份有限公司 | 用于治疗癫痫发作病症的药物组合物和方法 |
WO2022223099A1 (en) * | 2021-04-19 | 2022-10-27 | Symrise Ag | Compositions comprising cannabidiol and, optionally, bisabolol |
JP2024515891A (ja) * | 2021-04-30 | 2024-04-10 | プログレッシブ セラピューティクス インコーポレーテッド | 情緒障害の処置のためのケタミン及びカンナビス |
CN116159045B (zh) * | 2021-11-24 | 2024-03-19 | 四川大学华西医院 | ***二酚和/或次***二酚在制备局部***药效增强剂中的应用 |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4262003A (en) | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4767619A (en) | 1981-09-14 | 1988-08-30 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Burn wound dressing material |
GR79215B (pt) | 1982-06-07 | 1984-10-22 | Glaxo Group Ltd | |
US4511563A (en) | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
US5364628A (en) | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
GB8419575D0 (en) | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5016652A (en) | 1985-04-25 | 1991-05-21 | The Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
DE3710216A1 (de) | 1987-03-27 | 1988-10-06 | Rentschler Arzneimittel | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
PT88255B (pt) | 1987-08-13 | 1995-03-01 | Glaxo Group Ltd | Processo para a preparacao de derivados do indole |
US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4883660A (en) | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
MC2210A1 (fr) | 1990-06-07 | 1992-11-26 | Wellcome Found | Composes heterocycliques therapeutiques,leur utilisation et procede pour les preparer |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
AU651637B2 (en) | 1990-10-15 | 1994-07-28 | Pfizer Inc. | Indole derivatives |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
GB9103770D0 (en) | 1991-02-22 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
DE4314976C1 (de) | 1993-05-06 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5807571A (en) | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
WO1995005137A1 (en) | 1993-08-16 | 1995-02-23 | Cygnus Therapeutic Systems | Transdermal delivery system using a combination of permeation enhancers |
KR960015375B1 (ko) | 1994-06-08 | 1996-11-11 | 현대전자산업 주식회사 | 강유전체 박막 제조장치 및 그를 사용한 강유전체 박막 제조방법 |
US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
JP2000500449A (ja) | 1995-11-13 | 2000-01-18 | ピットミー・インターナショナル・ナムローゼ・フェンノートシャップ | 一酸化二窒素を含む鎮痛剤、抗炎症剤、および抗発熱剤のための投与媒体とそれらの医薬組成物 |
US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
US5872145A (en) | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
ES2234324T3 (es) | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6203796B1 (en) | 1999-07-08 | 2001-03-20 | Andreas D. Papaprodromou | Oregano-based therapeutic composition |
SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US20020165207A1 (en) | 2001-05-02 | 2002-11-07 | Richard Rosenbloom | Compositions and methods for the treatment of diabetic neuropathy |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
MXPA03006265A (es) | 2001-01-16 | 2004-06-25 | Purdue Research Foundation | Metodo de tratamiento de disfuncion relacionada con dopamina mediante administracion de un agonista de receptor de dopamina d1 completo, sin generacion de tolerancia. |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
EP1435945B1 (en) | 2001-06-05 | 2008-08-13 | Aung-din, Ronald | Topical migraine therapy |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US20030167556A1 (en) | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
CA2529528A1 (en) | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
US7825085B2 (en) | 2003-06-30 | 2010-11-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells |
US8263574B2 (en) * | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
CA2577219A1 (en) | 2004-10-01 | 2006-04-13 | Ache Laboratorios Farmaceuticos S.A. | Use of caryophyllenes in the manufacture of medicaments and treatment of bodily conditions of inflammation and inflammatory pain |
JP2009535370A (ja) | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
US8592424B2 (en) | 2008-06-30 | 2013-11-26 | Afgin Pharma Llc | Topical regional neuro-affective therapy |
WO2010036937A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
WO2010127033A1 (en) * | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
US20120202891A1 (en) | 2009-04-29 | 2012-08-09 | University Of Kentucky Research Foundation | Cannabinoid-Containing Compositions and Methods for Their Use |
LT2473475T (lt) * | 2009-08-31 | 2017-08-10 | Zynerba Pharmaceuticals, Inc. | Kanabidiolio provaisto panaudojimas vietiniam arba transderminiam įvedimui su mikroadatomis |
HUE026929T2 (en) * | 2010-10-19 | 2016-08-29 | Parenteral A S | Composition for treating inflammatory diseases comprising boswellic acids and cannabidol |
US20140030289A1 (en) | 2011-02-06 | 2014-01-30 | Rivka Ofir | Compositions comprising beta-caryophyllene and methods of utilizing the same |
WO2013009928A1 (en) | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
JP6326563B2 (ja) | 2012-03-19 | 2018-05-23 | アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド | β−カリオフィレンとCB2受容体アゴニストを用いた精神病の治療 |
US9345659B2 (en) | 2012-12-11 | 2016-05-24 | Avon Products, Inc. | Use of melicope extracts to improve conditions caused by excess lipids |
US9580400B2 (en) * | 2013-02-26 | 2017-02-28 | Northeastern University | Cannabinergic nitrate esters and related analogs |
EP3062774A2 (en) | 2013-10-31 | 2016-09-07 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
CA2956919C (en) * | 2014-07-21 | 2022-07-19 | Glia, Llc | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
AU2015385825A1 (en) * | 2015-03-10 | 2017-10-05 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
-
2016
- 2016-03-02 BR BR112017018944A patent/BR112017018944A2/pt not_active IP Right Cessation
- 2016-03-02 AU AU2016226267A patent/AU2016226267A1/en not_active Abandoned
- 2016-03-02 MX MX2017011280A patent/MX2017011280A/es unknown
- 2016-03-02 EP EP16759411.8A patent/EP3265081A4/en not_active Withdrawn
- 2016-03-02 CN CN201680025420.2A patent/CN107530318A/zh active Pending
- 2016-03-02 US US15/058,859 patent/US20160256410A1/en not_active Abandoned
- 2016-03-02 CA CA2978605A patent/CA2978605A1/en not_active Abandoned
- 2016-03-02 JP JP2017565040A patent/JP2018507262A/ja active Pending
- 2016-03-02 US US15/058,946 patent/US10716766B2/en active Active
- 2016-03-02 WO PCT/US2016/020446 patent/WO2016141056A1/en active Application Filing
-
2017
- 2017-06-02 US US15/612,375 patent/US20170266128A1/en not_active Abandoned
- 2017-09-03 IL IL254294A patent/IL254294A0/en unknown
-
2018
- 2018-04-03 HK HK18104400.6A patent/HK1244715A1/zh unknown
- 2018-06-28 HK HK18108330.2A patent/HK1248564A1/zh unknown
- 2018-07-12 US US16/033,899 patent/US10172809B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US10172809B2 (en) | 2019-01-08 |
US20160256410A1 (en) | 2016-09-08 |
EP3265081A1 (en) | 2018-01-10 |
US20180318237A1 (en) | 2018-11-08 |
HK1244715A1 (zh) | 2018-08-17 |
US10716766B2 (en) | 2020-07-21 |
CN107530318A (zh) | 2018-01-02 |
HK1248564A1 (zh) | 2018-10-19 |
EP3265081A4 (en) | 2018-11-21 |
JP2018507262A (ja) | 2018-03-15 |
US20170266128A1 (en) | 2017-09-21 |
WO2016141056A1 (en) | 2016-09-09 |
US20160256411A1 (en) | 2016-09-08 |
IL254294A0 (en) | 2017-10-31 |
MX2017011280A (es) | 2018-06-27 |
AU2016226267A1 (en) | 2017-09-28 |
CA2978605A1 (en) | 2016-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017018944A2 (pt) | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) | |
IL281566A (en) | Methods and systems for diagnosing and treating diseases | |
ZA201802351B (en) | Electrode system, device and method for the treatment of eye diseases, in particular dry eye | |
KR20180084980A (ko) | 진단 장치, 컴퓨터 프로그램, 및 진단 시스템 | |
BR112017015614A2 (pt) | produtos terapêuticos de glicano e métodos relacionados dos mesmos. | |
DK3472455T3 (da) | Kontrol- eller behandlingssystem og fremgangsmåde | |
BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
IL264301A (en) | Treatment of Fabry disease in ert-naive and ert-experienced patients | |
BR112015007758A2 (pt) | dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho. | |
BR112017002074A2 (pt) | vestuário e método de compressão médica terapêutica | |
BR112017020461A2 (pt) | sistema de monitoramento de paciente, e, método de monitoramento de um paciente em um quarto do paciente | |
BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
BR112015031471A2 (pt) | método e sistema de inspeção de segurança do corpo humano. | |
DK3065764T6 (da) | Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling | |
EP3398633A4 (en) | ADMINISTRATION DEVICE DESIGN SYSTEM, ADMINISTRATION SYSTEM, ADMINISTRATION DEVICE DESIGN METHOD, ADMINISTRATION DEVICE DESIGN PROGRAM, AND MEDICAL DEVICE DESIGN SYSTEM | |
ZA201800037B (en) | Diagnosis and treatment of infectious disease | |
SG11201703202YA (en) | Method and system for detection of disease agents in blood | |
IL269083A (en) | Methods for the prevention and treatment of heart diseases | |
FR3035569B1 (fr) | Article de bijouterie et/ou de joaillerie | |
SG11201800235RA (en) | Patient status determination device, patient status determination method and program | |
MA49633A (fr) | Agents, utilisations et procédés de traitement | |
DK2834643T3 (da) | Fremgangsmåde til behandling af blod, blodprodukter og organer | |
ITUA20163417A1 (it) | Fat and medical uses thereof | |
EP3342864A4 (en) | DIAGNOSTIC PROCEDURE FOR AUTOIMMUNE DISEASES, BIOMARKERS FOR THE DIAGNOSIS OF AUTOIMMUNE DISEASES AND ACTIVE AGGREGATE FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES | |
MA50358A (fr) | Sémaglutide en thérapie médicale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2620 DE 23/03/2021. |